ZYBERNO
Stock Report
Updated Aug 31, 2026

GAIN THERAPEUTICS, INC (GANX)

Healthcare • NASDAQ

$1.80

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
GAIN THERAPEUTICS, INC (GANX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-161.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-3,542.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GAIN THERAPEUTICS, INC (GANX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GANX generated -$20.96M in Owner Earnings. Reinvestment rate: 0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.80
Market Cap:$77.18M

Valuation Multiples (2)

P/B Ratio:6.84x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$66.30M

Price Action & Momentum (3)

Momentum Percentile:57 / 100
% of 52-Week High:41.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-118.4%
Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-17.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$23.09
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:13.7%
Latest Earnings Filed:2026-08-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.36x
Quick Ratio:4.36x
Cash Ratio:3.81x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-45.47x
Times Interest Earned:-45.47

Capital Structure (4)

Working Capital:11,535,883.00
Cash And Cash Equivalents:13,084,144.00
Long Term Debt:$220.06K
Net Debt:-$10.88M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$19.29M

Bottom Line Performance (3)

-$20.11M
Income Before Tax:-$19.20M
Ebitda Ttm:-19,199,636.00

Operating Expenses (5)

Operating Expenses:19,286,997.00
R And D Expense:10,098,343.00
Sga Expense:9,188,654.00
Income Tax Expense:$906.54K
Interest Expense:411,509.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$15.42M
Current Assets:$14.97M
Ppe Net:213,086.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:4,129,908.00
Current Liabilities:3,433,865.00
Long Term Debt:$220.06K
Short Term Debt:$1.98M

Equity & Capital (3)

Equity:$11.29M
Retained Earnings:-$111.64M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,220,365.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:566,049.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.37M-$20.96M

Investment Activities (1)

Investing Cash Flow:-$43.45K

Financing Activities (3)

Financing Cash Flow:$404.32K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:10,100,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:87,361.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.50
-$0.50
Earnings Per Share Ttm:-$0.47

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.43

Book Value & Capital (2)

Book Value Per Share:$0.26
Cash Per Share:0.31

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$20.96M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-17.5%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-21.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:GANX
Company Name:GAIN THERAPEUTICS, INC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:42.88M
Shares Outstanding Basic:42.88M
Shares Outstanding Diluted:42.88M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 22:53:49 UTC
Data Timestamp:2026-08-20T02:21:52.368999
Scroll to Top